Efanesoctocog alfa is the first factor VIII therapy to be awarded Breakthrough Therapy designation by the FDA. Designation is based on XTEND-1 Phase 3 study data demonstrating a clinically meaningful prevention of bleeds and superiority in prevention of bleeding episodes.
💼 Business Developments:
✅ Partnership/Collaboration
❌ Acquisition Activity: Not reported
❌ Licensing Agreement: Not reported
✅ Regulatory Milestone
❌ Leadership Updates: Not reported
📞 Contact Information:
Media Contact: s, click here. Investor Relations 2/3 For details on how to contact the Sobi Inv
🌍 Sanofi (SNY) - Form 6-K Filing
Filing Date: 2022-06-07
Accepted: 2022-06-07 14:51:30
Event Type: Clinical Trial Update
Event Details:
💼 Business Developments:
📞 Contact Information: